Exhibit 99.1

                                [ORAGENICS LOGO]

Contact:                                                              For Media:

Chuck Soponis                                                      Joan Kureczka
Chief Executive Officer                                             Jesse Fisher
Oragenics, Inc.                                       Kureczka/Martin Associates
(386) 418-4018                                                    (415) 821-2413
                                                               Jkureczka@aol.com

FOR IMMEDIATE RELEASE

            FDA LIFTS CLINICAL HOLD ON ORAGENICS' NOVEL TREATMENT FOR
                          PREVENTION OF DENTAL CARIES

COMPANY ANTICIPATES BEGINNING PHASE I STUDY OF REPLACEMENT THERAPY IN EARLY 2005

ALACHUA, FL (NOVEMBER 30, 2004): Oragenics, Inc. (AMEX:ONI) reported today that
the U.S. Food and Drug Administration (FDA) has agreed to lift the clinical hold
on the company's Replacement Therapy for the treatment of dental caries. The
FDA's clearance to proceed with a Phase I safety trial came following the
agency's completed review of the study's clinical design and the unanimous vote
of the Recombinant DNA Advisory Committee (RAC) on March 15, 2004 that the first
human clinical study of Oragenics Replacement Therapy be carried out under the
protocol proposed by the company. The FDA had placed Oragenics' original
Investigational New Drug application (IND) on clinical hold in May 2003, pending
further review of the study design.

"We are extremely pleased to reach agreement with the FDA on a clinical protocol
that adequately addresses the potential safety questions posed by the first
human clinical trial of our novel Replacement Therapy," said Chuck Soponis,
Oragenics' president and chief executive officer. "We anticipate initiating
Phase I human clinical safety testing of our Replacement Therapy early in 2005."

ABOUT REPLACEMENT THERAPY

Replacement Therapy is a single, painless topical treatment that could in theory
offer life-long protection from most tooth decay. Tooth decay is caused by
lactic acid produced by a bacterium in the mouth called Streptococcus mutans.
Oragenics' Replacement Therapy employs a patented, genetically modified strain
of S. mutans that does not produce this decay-producing acid. When applied to a
person's teeth by a dentist, this engineered bacterium displaces the resident
acid-producing bacterium, providing potentially life-long protection against
most dental decay. Replacement therapy is the result of 25 years of research by
Oragenics' founder and chief scientific officer, Jeffrey Hillman, DMD, PhD, a
noted molecular geneticist and expert on oral microbiology. Oragenics plans to
complete Phase I safety testing for Replacement Therapy and to partner with a
major healthcare products or pharmaceutical firm prior to initiating later
stages of clinical development.


                                   -- More --


FDA LIFTS CLINICAL HOLD ON TRIAL OF ORAGENICS' NOVEL TREATMENT
FOR PREVENTION OF DENTAL CARIES
PAGE 2


ABOUT ORAGENICS

Oragenics, Inc. is an emerging biotechnology company focused on the development
and licensure of innovative products and technologies for improving human
health. The company's lead product is a novel oral rinse for the prevention of
tooth decay, which is anticipated to enter clinical trials in early 2005. The
company is also developing a novel antibiotic with broad-spectrum activity
against gram-positive bacteria and a probiotic product aimed at maintaining oral
health. The company is headquartered in Alachua, Florida. For more information
about Oragenics, please consult the company's website at www.oragenics.com.

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF
1995: This release includes forward-looking statements which reflect Oragenics'
current views with respect to future events and financial performance. These
forward-looking statements are based on management's beliefs and assumptions and
information currently available. The words "believe", "expect", "anticipate",
"intend", "estimate", "project" and similar expressions which do not relate
solely to historical matters identify forward-looking statements. Investors
should be cautious in relying on forward-looking statements because they are
subject to a variety of risks, uncertainties, and other factors that could cause
actual results to differ materially from those expressed in any such
forward-looking statements. These factors include, but are not limited to (1)
the ability to successfully complete development and commercialization of
Oragenics' Replacement Therapy for prevention of tooth decay, novel antibiotic,
and probiotic product for oral health; (2) the ability to obtain substantial
additional funding; (3) the ability to develop and commercialize products before
competitors;)4) the ability to develop commercial products with the in-licensed
technology; and (5)) other factors detailed from time to time in filings with
the Securities and Exchange Commission. We expressly disclaim any responsibility
to update forward-looking statements.

                                      # # #